title: Characterization of treatment resistant depression episodes in a cohort of patients from a US commercial claims database.
abstract: BACKGROUND
  Treatment Resistant Depression (TRD) is a significant and burdensome health concern.
  
  
  OBJECTIVE
  To characterize, compare and understand the difference between TRD and non-TRD patients and episodes in respect of their episode duration, treatment patterns and healthcare resource utilization.
  
  
  METHODS
  Patients between 18 and 64 years with a new diagnosis of major depressive disorder (MDD) and without a previous or comorbid diagnosis of schizophrenia or bipolar disease were included from PharMetrics Integrated Database, a claims database of commercial insurers in the US. Episodes of these patients in which there were at least two distinct failed regimens involving antidepressants and antipsychotics were classified as TRD.
  
  
  METHODS
  82,742 MDD patients were included in the analysis; of these patients, 125,172 episodes were identified (47,654 of these were drug-treated episodes).
  
  
  METHODS
  Comparison between TRD and non-TRD episodes in terms of their duration, number and duration of lines of treatment, comorbidities, and medical resource utilization.
  
  
  RESULTS
  Of the treated episodes, 6.6% (N = 3,134) met the criteria for TRD. The median time to an episode becoming TRD was approximately one year. The mean duration of a TRD episode was 1,004 days (vs. 452 days for a non-TRD episode). More than 75% of TRD episodes had at least four lines of therapy; half of the treatment regimens included a combination of drugs. Average hospitalization costs were higher for TRD than non-TRD episodes: $6,464 vs. $1,734, as were all other health care utilization costs.
  
  
  CONCLUSIONS
  While this study was limited to relatively young and commercially covered patients, used a rigorous definition of TRD and did not analyze for cause or consequence, the results highlight high unmet medical need and burden of TRD on patients and health care resources.
authors.affiliation: Janssen-Cilag GmbH, Market Access, Global Commercial Strategy Organization, Neuroscience, Janssen-Cilag GmbH, Neuss, Germany.
authors.forename: Nicole
authors.initials: N
authors.lastname: Kubitz
authors.forename: Maneesha
authors.initials: M
authors.lastname: Mehra
authors.forename: Ravi C
authors.initials: RC
authors.lastname: Potluri
authors.forename: Nitesh
authors.initials: N
authors.lastname: Garg
authors.forename: Nicole
authors.initials: N
authors.lastname: Cossrow
mesh_terms: D000293:Adolescent; D000328:Adult; D000928:Antidepressive Agents / Q000145:classification / Q000191:economics / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000191:economics; D015331:Cohort Studies; D016208:Databases, Factual / Q000706:statistics & numerical data*; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D061218:Depressive Disorder, Treatment-Resistant / Q000188:drug therapy* / Q000523:psychology; D004359:Drug Therapy, Combination; D017050:Episode of Care; D005260:Female; D006760:Hospitalization / Q000191:economics; D006801:Humans; D007345:Insurance Claim Review / Q000706:statistics & numerical data*; D008297:Male; D008875:Middle Aged; D017063:Outcome Assessment, Health Care / Q000191:economics; D055815:Young Adult
chemical_list: D000928:Antidepressive Agents; D014150:Antipsychotic Agents